Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients
Open accessThe DOI matches its OpenAlex record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A key challenge to dose selection in early central nervous system (CNS) clinical drug development is that patient tolerability profiles often differ from those of healthy volunteers (HVs), yet HVs are the modal population for determining doses to be investigated in phase II trials. Without clear tolerability data from the target patient population, first efficacy trials may include doses that are either too high or too low, creating undue risk for study participants and the development program overall. Bridging trials address this challenge by carefully investigating safety and tolerability in the target population prior to full-scale proof-of-concept trials. OBJECTIVE: Org 26576 is an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor positive allosteric modulator that acts by modulating ionotropic AMPA-type glutamate receptors to enhance glutamatergic neurotransmission. In preparation for phase II efficacy trials in major depressive disorder (MDD), two separate phase I trials were conducted to evaluate safety, tolerability, and pharmacokinetics in HVs and in the target patient population. METHODS: Both trials were randomized and placebo controlled, and included multiple rising-dose cohorts (HV range 100-400 mg bid; MDD range 100-600 mg bid). HVs (n = 36) and patients with MDD (n = 54) were dosed under similarly controlled conditions in an inpatient facility, HVs for up to 14 days and MDD patients for up to 28 days. Safety, tolerability, and pharmacokinetics were assessed frequently. RESULTS: Despite comparable pharmacokinetic profiles, the maximum tolerated dose (MTD) in depressed patients was 450 mg bid, twice the MTD established in HVs. No clinically relevant safety issues associated with Org 26576 were noted. CONCLUSION: This article presents safety, tolerability, and pharmacokinetic data from two different populations examined under similar dosing conditions. The important implications of such bridging work in phase II dose selection are discussed, as are study design and data interpretation challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Correlation between plasma levels of glutamate, alanine and serine with severity of depression
Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C. R., & Kawahara, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.036 · Cited by 332
A role for AMPA receptors in mood disorders
Alt, A., Nisenbaum, E. S., Bleakman, D., & Witkin, J. M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.022 · Cited by 238 · cited 1×
“It has been suggested that modulation of these cellular activities may, in part, play a role in the mode of action of current antidepressant agents.([28,29]) If so, AMPA PAMs represent a promising novel approach in MDD.”
Du, J., Gray, N. A., Falke, C. A., Chen, W., Yuan, P., Szabo, S. T., Einat, H., & Manji, H. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1258-04.2004 · Cited by 157 · cited 1×
“AMPA receptors mediate fast excitatory neurotransmission in the brain, and their activation has been reported to exert a variety of cellular effects, including enhancement of neurotrophic factor activity (particularly brain-derived neurotrophic factor [BDNF]),([25]) synaptic plasticity,([26]) and neurogenesis.”
Bai, F., Bergeron, M., & Nelson, D. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00104-7 · Cited by 144 · cited 1×
“AMPA receptors mediate fast excitatory neurotransmission in the brain, and their activation has been reported to exert a variety of cellular effects, including enhancement of neurotrophic factor activity (particularly brain-derived neurotrophic factor [BDNF]),([25]) synaptic plasticity,([26]) and neurogenesis.([27]) I…”
Cited by
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Metadata
- Authors
- Nations, K. R., Bursi, R., Dogterom, P., Ereshefsky, L., Gertsik, L., Mant, T., & Schipper, J.
- Venue
- Drugs in R&D
- Publisher
- Adis, Springer Healthcare
- Published
- 2012-09-01
- Volume
- 12
- Issue
- 3
- Pages
- 127-139
- ISSN
- 1174-5886 (ISSN-L)
- OpenAlex
- W2071430187
- Cited by
- 23
- References
- 5
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.